We're adding to our position in this life sciences firm with the market highly oversold

  • 📰 CNBC
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 72%

United States News News

United States United States Latest News,United States United States Headlines

The purchase is on the smaller side because we are hesitant to put too much money to work in a volatile market.

We are buying 25 shares of Danaher , at roughly $250.48 apiece. Following Tuesday's trade, Jim Cramer's Charitable Trust will be own 520 shares of DHR, increasing its weighting in the portfolio to 4.58% from 4.37%. Our purchase of additional shares of the life-sciences-and-medical-diagnostics firm Danaher on Tuesday is on the smaller side because we are hesitant to put too much money to work in a volatile market.

Our approach amid the August pullback has been to purchase high-quality companies that have reported strong quarters and provided positive forward guidance this earnings season. Danaher is a slight deviation from the plan because the company reported only a modest earnings beat and slightly cut its full-year outlook due to ongoing weakness in the bioprocessing market.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in US

United States United States Latest News, United States United States Headlines